Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 76.20
- Piotroski Score 2.00
- Grade Outperform
- Symbol (PCVX)
- Company Vaxcyte, Inc.
- Price $106.53
- Changes Percentage (-0.71%)
- Change -$0.76
- Day Low $103.72
- Day High $107.99
- Year High $121.06
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $140.00
- High Stock Price Target $163.00
- Low Stock Price Target $58.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.29
- Trailing P/E Ratio -16.54
- Forward P/E Ratio -16.54
- P/E Growth -16.54
- Net Income $-402,266,000
Income Statement
Quarterly
Annual
Latest News of PCVX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Should You Consider Investing in Vaxcyte (PCVX)?
Baron Funds released their Q3 2024 investor letter for the Baron Health Care Fund, reporting a 5.81% appreciation in the quarter. Vaxcyte, Inc. was highlighted as a top pick, with a one-month return o...
By Yahoo! Finance | 3 days ago -
Vaxcyte, Inc. (PCVX): Among Hedge Funds' Top Biotech Stock Picks
An article discusses the risks and potential returns associated with investing in biotech stocks, focusing on Vaxcyte, Inc. (NASDAQ:PCVX) and its progress in developing anti-bacterial treatments....
By Yahoo! Finance | 1 month ago -
Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)
Vaxcyte Inc is a biotech company focusing on vaccine development for infectious diseases. Recent insider selling trend indicates $229,020 transaction with no insider buys. Investors can analyze market...
By Yahoo! Finance | 4 months ago
